Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib

IMPORTANCE: When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account. OBJECTIVES: To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Netw Open
Main Authors: de Almeida Carvalho, Lelia Maria, de Oliveira Sapori Avelar, Sandra, Haslam, Alyson, Gill, Jennifer, Prasad, Vinay
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902826/
https://ncbi.nlm.nih.gov/pubmed/31755953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.16091
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki